What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?

Figures & data

Table 1. Summary of efficacy and toxicity data for loncastuximab tesirine and camidanlumab tesirine in single-agent phase 1 and phase 2 clinical trials.

Clinical Trial	Indication	Number of patients	Dose ($\mu$g/kg)	ORR (%)	CR (%)	mDoR (Months)	mPFS (Months)	mOS (Months)	Most common grade ≥3 TEAEs
Loncastuximab tesirine
Phase 1 [2]	R/R B-cell non-Hodgkin lymphoma	180	15–200	45.6	26.7	5.4	3.1	8.3	Neutropenia Thrombocytopenia Increased GGT
	Diffuse large B-cell lymphoma	139	15–200	42.3	23.4	4.5	2.8	7.5
	Mantle cell lymphoma	15	15–200	46.7	33.3	n.r	4.8	n.r.
	Follicular lymphoma	14	15–200	78.6	64.3	n.r.	n.d	n.r.
Phase 2 [3]	R/R Diffuse large B-cell lymphoma	145	150/75^a	48.3	24	10.3^c (13.4 with CR)	4.9	9.9	Neutropenia Thrombocytopenia Increased GGT
Camidanlumab tesirine
Phase 1 [4]	R/R Lymphoma	130	5–300	58	29				Increased GGT Maculopapular rash Anemia
	Non-Hodgkin lymphoma	53	5–300	38	9
	Classical Hodgkin lymphoma	77	5–300	71	42	6.6	6.8	n.r.
	Classical Hodgkin lymphoma	37	45	86	49	7.2	7	n.r.
Phase 2 [5]	R/R Classical Hodgkin lymphoma	117	45/30^b	70.1	33.3	13.7 (14.5 with CR)	9.1 (15.9 with CR)		Thrombocytopenia Anemia, Neutropenia Hypophosphatemia Maculopapular rash

n.r. – not reached. n.d. – not determined due to low numbers, ORR – overall response rate (CR + PR), CR – complete responses, mDoR – median duration of response, mPFS – median progression free survival, mOS – median overall survival. TEAE – treatment-emergent adverse events, R/R – relapsed or refractory. GGT – gamma-glutamyltransferase.

^a150 $\mu$g/kg for two cycles followed by 75 $\mu$g/kg for subsequent cycles.

^b45 $\mu$g/kg for two cycles followed by 30 $\mu$g/kg for subsequent cycles.

^cMedian time to first response was 41 days.

Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634–2645. doi: 10.1182/blood.2020007512

 PubMed Web of Science ®Google Scholar

Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790–800. doi: 10.1016/S1470-2045(21)00139-X

 PubMed Web of Science ®Google Scholar

Hamadani M, Collins GP, Caimi PF, et al. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Lancet Haematol. 2021;8(6):e433–e445. doi: 10.1016/S2352-3026(21)00103-4

 PubMed Web of Science ®Google Scholar

Carlo-Stella C, Ansell S, Zinzani PL, et al. S201: Camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical hodgkin lymphoma (r/r chl). (Abstract) HemaSphere. 2022;6:102–103. doi: 10.1097/01.HS9.0000843696.37630.1c

 Google Scholar